43,900 Shares in Aquestive Therapeutics, Inc. (NASDAQ:AQST) Bought by MONECO Advisors LLC

MONECO Advisors LLC purchased a new position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) in the fourth quarter, HoldingsChannel reports. The fund purchased 43,900 shares of the company’s stock, valued at approximately $156,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in AQST. Creative Planning increased its stake in shares of Aquestive Therapeutics by 39.3% in the third quarter. Creative Planning now owns 92,822 shares of the company’s stock worth $462,000 after buying an additional 26,185 shares during the last quarter. International Assets Investment Management LLC bought a new stake in shares of Aquestive Therapeutics in the third quarter worth $990,000. Financial Advocates Investment Management increased its stake in shares of Aquestive Therapeutics by 14.7% in the third quarter. Financial Advocates Investment Management now owns 39,000 shares of the company’s stock worth $194,000 after buying an additional 5,000 shares during the last quarter. Janney Montgomery Scott LLC increased its stake in shares of Aquestive Therapeutics by 4.9% in the third quarter. Janney Montgomery Scott LLC now owns 923,285 shares of the company’s stock worth $4,598,000 after buying an additional 42,800 shares during the last quarter. Finally, Harvey Capital Management Inc. bought a new stake in Aquestive Therapeutics during the third quarter valued at $88,000. Institutional investors own 32.45% of the company’s stock.

Analysts Set New Price Targets

Several research firms have weighed in on AQST. Cantor Fitzgerald began coverage on shares of Aquestive Therapeutics in a research note on Tuesday, December 17th. They set an “overweight” rating and a $17.00 target price for the company. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Aquestive Therapeutics in a research note on Friday, December 20th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Aquestive Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $11.00.

Aquestive Therapeutics Stock Performance

Shares of AQST opened at $2.80 on Wednesday. Aquestive Therapeutics, Inc. has a 1 year low of $2.24 and a 1 year high of $6.23. The company has a market cap of $255.30 million, a price-to-earnings ratio of -6.22 and a beta of 2.67. The firm has a fifty day moving average of $3.23 and a 200-day moving average of $4.18.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.